Jiri Blazek

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Real-world PD-L1 testing, fi rst-line therapy for advanced NSCLC, and fi rst-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic.

Real-world PD-L1 testing, fi rst-line therapy for advanced NSCLC, and fi rst-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: August 05, 2025

Energy Spectrum of Ultrahigh-Energy Cosmic Rays across Declinations -90° to +44.8° as Measured at the Pierre Auger Observatory.

Energy Spectrum of Ultrahigh-Energy Cosmic Rays across Declinations -90° to +44.8° as Measured at the Pierre Auger Observatory.

Journal: Physical review letters

Published: June 16, 2025

Inference of the Mass Composition of Cosmic Rays with Energies from 10^{18.5} to 10^{20} eV Using the Pierre Auger Observatory and Deep Learning.

Inference of the Mass Composition of Cosmic Rays with Energies from 10^{18.5} to 10^{20} eV Using the Pierre Auger Observatory and Deep Learning.

Journal: Physical review letters

Published: June 10, 2024

Omission of staging PET/CT linked to reduced survival in stage III non-small cell lung cancer: insights from the LUCAS project real-world data.

Omission of staging PET/CT linked to reduced survival in stage III non-small cell lung cancer: insights from the LUCAS project real-world data.

Journal: Translational lung cancer research

Published: January 30, 2024

Search for the Anomalous Events Detected by ANITA Using the Pierre Auger Observatory.

Search for the Anomalous Events Detected by ANITA Using the Pierre Auger Observatory.

Journal: Physical review letters

Published: January 17, 2024

Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer.

Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer.

Journal: In vivo (Athens, Greece)

Published: May 21, 2023

Demonstrating Agreement between Radio and Fluorescence Measurements of the Depth of Maximum of Extensive Air Showers at the Pierre Auger Observatory.

Demonstrating Agreement between Radio and Fluorescence Measurements of the Depth of Maximum of Extensive Air Showers at the Pierre Auger Observatory.

Journal: Physical review letters

Published: March 30, 2023

Neo/adjuvant immunotherapy in the treatment of nonsmall cell lung cancer.

Neo/adjuvant immunotherapy in the treatment of nonsmall cell lung cancer.

Journal: Vnitrni lekarstvi

Published: October 11, 2022

Bronchial Asthma as a Cardiovascular Risk Factor: A Prospective Observational Study.

Bronchial Asthma as a Cardiovascular Risk Factor: A Prospective Observational Study.

Journal: Biomedicines

Published: September 17, 2022

Limits to Gauge Coupling in the Dark Sector Set by the Nonobservation of Instanton-Induced Decay of Super-Heavy Dark Matter in the Pierre Auger Observatory Data.

Limits to Gauge Coupling in the Dark Sector Set by the Nonobservation of Instanton-Induced Decay of Super-Heavy Dark Matter in the Pierre Auger Observatory Data.

Journal: Physical review letters

Published: August 09, 2022

Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer.

Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer.

Journal: Translational cancer research

Published: February 07, 2022

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

Journal: Anticancer research

Published: January 20, 2022

Showing 1-12 of 28

Last Updated: 09/26/2026